Promising role of voxelotor in managing sickle cell disease in children: a narrative review
Open Access
- 15 February 2025
- journal article
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 68 (2) , 106-114
Abstract
Sickle cell disease (SCD) is characterized by chronic hemolytic anemia and intermittent vasoocclusive crises. To date, 4 disease-modifying drugs have been approved for the treatment of SCD: hydroxyurea (an S-phase inhibitor), L-glutamine (an amino acid), crizanlizumab (a P-selectin inhibitor), and voxelotor (a hemoglobin S polymerization inhibitor). Preclinical studies suggested that voxelotor effectively treats SCD and sickle cell anemia (SCA). In a phase III trial, voxelotor-treated patients showed significantly elevated hemoglobin levels (>1 g/dL from baseline) compared to placebo-treated patients. The group that received voxelotor also showed a greater decrease in hemolytic markers but a comparable incidence of side effects. Six ongoing clinical trials also sought to ascertain the effectiveness and safety of high-dose voxelotor when administered to children younger than 12 years. Studies assessing their long-term efficacy and safety are needed to fully understand the role of voxelotor in treating SCD/SCA. In this review, we discuss the mechanisms, trials to date, and future treatment directions of voxelotor.Keywords
This publication has 39 references indexed in Scilit:
- Effect of voxelotor on cardiopulmonary testing in youths with sickle cell anemia in a pilot studyPediatric Blood & Cancer, 2023
- Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 yearsPediatric Blood & Cancer, 2022
- Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Haematology, 2021
- Accelerated approval of Oxbryta® (voxelotor): A case study on novel endpoint selection in sickle cell diseaseContemporary Clinical Trials, 2020
- Systematic Review of Voxelotor: A First‐in‐Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell DiseasePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2020
- Pathophysiology and recent therapeutic insights of sickle cell diseaseAnnals of Hematology, 2020
- Voxelotor: First ApprovalDrugs, 2020
- Case series of patients with severe sickle cell disease treated with voxelotor (GBT440) by compassionate accessAmerican Journal of Hematology, 2018
- Sickle hemoglobin oxygen affinity‐shifting strategies have unequal cerebrovascular risksAmerican Journal of Hematology, 2017
- High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell diseaseThe Journal of Pediatrics, 1991